Introduction
============

Gastric cancer (GC) is the fourth most common malignancy with \~1 million patients diagnosed with GC worldwide per year, and the second leading cause of cancer-related mortality worldwide with 800,000 fatalities per year ([@b1-ol-06-06-1693]), though the prevalence and mortality of GC have gradually decreased ([@b2-ol-06-06-1693]). In China, \~0.4 million new cases of GC and 0.3 million fatalities occurred each year, making it the third leading cause of cancer-related mortality ([@b3-ol-06-06-1693]). In addition, the outcome of GC remains poor with a 5-year survival rate of only \~20--25% ([@b4-ol-06-06-1693]).

Accurate prediction of the prognosis of patients with GC is crucial, as surgery is the most important therapeutic approach ([@b5-ol-06-06-1693]). It helps to define which patients with GC should receive secondary treatments, such as chemotherapy and/or radiotherapy, which are largely dependent on clinical staging ([@b6-ol-06-06-1693],[@b7-ol-06-06-1693]).

The prognosis of GC is closely related to the tumor stage, including the depth of tumor invasion, lymph node status and distant metastases ([@b8-ol-06-06-1693]--[@b10-ol-06-06-1693]). The most commonly used staging system of GC is proposed by the American Joint Committee on Cancer (AJCC) and is known as the AJCC tumor-node-metastases (TNM) staging system. In 2010, the 7th edition of the AJCC gastric cancer staging manual was ascertained, resulting in much controversy ([@b11-ol-06-06-1693]). Certain studies confirmed that the 7th AJCC TNM staging system was superior to the 6th AJCC TNM staging system ([@b12-ol-06-06-1693]--[@b14-ol-06-06-1693]), while other studies confirmed the 6th was better for prognostic stratification ([@b15-ol-06-06-1693],[@b16-ol-06-06-1693]).

In recent years, lymph node ratio (LNR), defined as the ratio of the number of metastatic lymph nodes (LNs) to the number of removed LNs, has gained increasing attention in researches because of its lymph node status (pN) in AJCC TNM staging system ([@b17-ol-06-06-1693]--[@b19-ol-06-06-1693]). However, the analytical methods of these studies were commonly the same and no in depth investigations have been conducted.

In this study, GC patients with radical resection and extended lymphatic resection were selected, as R0 resection with D2 lymphadenectomy is regarded as the standard surgical technique in Eastern Asian countries ([@b7-ol-06-06-1693]). Comprehensive analytical methods were used to evaluate whether LNR was a superior prognosticator compared with pN for GC.

Patients and methods
====================

Patients
--------

This retrospective study initially consisted of 613 patients with GC who underwent resection from three tertiary referral hospitals from January 2004 to August 2011. All the clinicopathological information was available, including demographic variables, underlying co-morbidities, surgical modality, lab and image study information, pathological reports, pre- and postoperative therapies, and follow-up information. Among these patients with GC, only those who had \>15 LNs resected and radical resection were enrolled into the final study. Patients who had palliative resection, ≤15 LNs resected and incomplete follow-up information were excluded, as this method was more suitable for those patients with \>15 LNs resected. In total, 138 patients were enrolled into the final study.

The patients were followed up every 3 months during the first 2 years after surgery, every 6 months during the third postoperative year and every year thereafter. All the follow-up information was entered into a database.

Tumor-node-ratio-metastases (TRM) staging system
------------------------------------------------

For defining the TRM staging system, two recognized methods were used to determine the best cut-off points for LNR. One was the commonly used cut-off approach using the log-rank test, the other was X-tile as reported by Wang *et al*([@b17-ol-06-06-1693]). X-tile determines the optimal cut-off points of LNR by taking LNR as a continuous variable. Compared with the commonly used cut-off approach, X-tile controls for the inflated type I error problem and minimizes information loss. LNR was then substituted for pN in the 7th AJCC TNM staging system to generate the TRM staging system as the N classification of the 7th AJCC TNM staging system is thought to be superior ([@b13-ol-06-06-1693]).

Statistical analysis
--------------------

All data were analyzed using SPSS 17.0 statistical software package (SPSS, Inc., Chicago, IL, USA). Pearson\'s correlation coefficient (r) was used to study the correlations among the number of removed LNs, pN and LNR. The Kaplan-Meier survival curve was used to study the survival status, and the log-rank test and Cox proportional hazards model were used to identify the independent factors for survival. Receiver operating characteristic (ROC) curve analysis was used to determine the predictive value of the parameters. Two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Characteristics of patients
---------------------------

Among 613 GC patients who had undergone resection from three tertiary referral hospitals between January 2004 and August 2011, 138 were enrolled into the final study. By the time of the last follow-up (May 31, 2012), 76 mortalities had occurred. The median number of removed LNs was 21 (range 16--47). The median age of patients was 56 years (range 27--79 years), and the male-to-female ratio was 2.54 to 1. Detailed information is listed in [Table I](#tI-ol-06-06-1693){ref-type="table"}.

TRM staging system
------------------

According to the commonly used cut-off approach by the log-rank test, three cut-off points were generated: 0, 0.50 and 0.80. According to X-tile (<http://www.tissuearray.org/rimmlab/>), patients with LNR=0 were fixed into one group, as it has been demonstrated that their prognosis was significantly different from patients with LNR \>0 ([@b20-ol-06-06-1693]). The remaining patients were analyzed and the two other cut-off points were 0.48 and 0.79. Considering the log-rank test results and clinical feasibility, the final cut-off points for LNR were set as 0, 0.5 and 0.8. Four subgroups were then determined (R0, LNR=0; R1, LNR ≤0.5; R2, 0.5\> LNR ≤0.8; and R3, LNR \>0.8), and the TRM staging system was generated. Compared with the 7th AJCC TNM staging system, 55 (39.9%) GC patients were downstaged and no patients were upstaged in the TRM staging system ([Fig. 1](#f1-ol-06-06-1693){ref-type="fig"}).

Correlations between the number of removed LNs, pN and LNR
----------------------------------------------------------

There was a significant correlation between the number of removed LNs and pN (r=0.228, P=0.001) ([Fig. 2A](#f2-ol-06-06-1693){ref-type="fig"}). There was no significant correlation between the number of removed LNs and LNR (r=0.019, P=0.825) ([Fig. 2B](#f2-ol-06-06-1693){ref-type="fig"}). The difference between pN and LNR was statistically significant (r=0.931, P\<0.001) ([Fig. 2C](#f2-ol-06-06-1693){ref-type="fig"}). These results demonstrated that LNR was not influenced by surgery; however, pN was.

Univariate and multivariate analyses
------------------------------------

By the Kaplan-Meier curve and log-rank test, nine factors were identified as possible determinants on overall survival (OS), including cancer site (P=0.020), tumor invasion (P=0.004), pN (P\<0.001), LNR (P\<0.001), distant metastases (P\<0.001), TNM staging (P\<0.001), TRM staging (P\<0.001), surgery type (P=0.044) and postoperative serious adverse events (SAEs) (P\<0.001). All factors were then integrated into multivariate analysis using Cox proportional hazards model, and both LNR and pN were found to be independent prognostic factors ([Table II](#tII-ol-06-06-1693){ref-type="table"}).

Comparison of the discriminative power between pN and LNR for OS
----------------------------------------------------------------

The median OS of R0, R1, R2 and R3 was 64.4 months \[95% confidence interval (CI), 50.9--77.9 months\], 37.8 months (95% CI, 19.6--56.0 months), 13.8 months (95% CI, 6.4--21.2 months) and 7.5 months (95% CI, 2.2--12.7 months), respectively (P\<0.001, overall comparison; P=0.071 for R0 vs. R1; P\<0.001 for R1 vs. R2; and P=0.001 for R2 vs. R3) ([Fig. 3A](#f3-ol-06-06-1693){ref-type="fig"}). In comparison, the median OS of N0, N1, N2 and N3 was 64.4 months (95% CI, 50.9--77.9 months), 61.5 months (95% CI, 44.4--78.6 months), 27.0 months (95% CI, 15.4--38.6 months) and 14.6 months (95% CI, 8.4--20.8 months), respectively (P\<0.001, all overall comparison; P=0.597 for N0 vs. N1; P=0.168 for N1 vs. N2; P=0.122 for N2 vs. N3) ([Fig. 3B](#f3-ol-06-06-1693){ref-type="fig"}). Therefore, LNR could better differentiate OS than LN.

Comparison of the discriminative power between TRM staging and TNM staging for OS
---------------------------------------------------------------------------------

At the median follow-up of 38.3 months (range, 9.9--97.7 months), the median OS was 23.9 months (95% CI, 18.8--29.0 months), and the 1-, 2-, 3- and 5-year survival rates were 76.8, 57.2, 50.0 and 46.4%, respectively. Based on the TRM staging, the median OS of stages I, II, IIIA, IIIB, IIIC and IV was 77.2 months (95% CI, 63.4--91.0 months), 44.3 months (95% CI, 33.4--55.1 months), 36.4 months (95% CI, 4.3--68.5 months), 25.0 months (95% CI, 10.1--39.9 months), 11.3 months (95% CI, 9.1--13.5 months) and 11.4 months (95% CI, 2.1--20.7 months), respectively (P\<0.001, overall comparison; P=0.228 for I vs. II; P=0.490 for II vs. IIIA; P=0.173 for IIIA vs. IIIB; P\<0.001 for IIIB vs. IIIC, P=0.072 for IIIC vs. IV) ([Fig. 4A](#f4-ol-06-06-1693){ref-type="fig"}). By comparison, the median OS of stages I, II, IIIA, IIIB, IIIC and IV of TNM staging was 77.2 months (95% CI, 63.4--91.0 months), 43.4 months (95% CI, 32.3--54.5 months), 64.5 months (95% CI, 47.7--81.3 months), 28.0 months (95% CI, 25.0--31.0 months), 14.6 months (95% CI, 8.6--20.5 months) and 11.4 months (95% CI, 2.1--20.7 months), respectively (P\<0.001, overall comparison; P=0.190 for I vs. II; P=0.786 for II vs. IIIA; P=0.180 for IIIA vs. IIIB; P=0.181 for IIIB vs. IIIC, P=0.212 for IIIC vs. IV) ([Fig. 4B](#f4-ol-06-06-1693){ref-type="fig"}). TRM staging was capable of discriminating stages IIIB and IIIC, but TNM staging could not discriminate any neighboring subgroups.

Predictive accuracy
-------------------

The predictive value of the LNR classification, pN classification, TRM staging system and TNM staging system was further studied by ROC analysis. All of the factors predicted mortality precisely (P\<0.01) ([Table III](#tIII-ol-06-06-1693){ref-type="table"}). The TRM staging system was better to predict the clinical outcomes than the TNM staging system, and LNR was better than pN ([Fig. 5](#f5-ol-06-06-1693){ref-type="fig"}).

Discussion
==========

Due to the shortcomings of the AJCC TNM staging system, increasing numbers of investigators have shifted their attention to looking for an optimal method. The most popular and the most recognized optimal method was the TRM staging system based on LNR. [Table IV](#tIV-ol-06-06-1693){ref-type="table"} lists a number of previous studies on LNR, and these studies confirmed the superiority of the LNR and TRM staging system compared with the AJCC TNM staging system through univariate and multivariate analysis and Kaplan-Meier survival curves ([@b8-ol-06-06-1693]). In the present study, the cut-off points were 0, 0.50 and 0.80.

In our previous study of GC, patients with stage IIIB and beyond had much poorer OS than other patients. In this study, stage IIIB and beyond accounted for \>60% of patients in TNM staging, but \<45% in TRM staging, as 24 (17.4%) patients were downstaged to stage IIIA. The prognosis of patients with different classifications could apparently be discriminated, and this may provide a basis for determining secondary treatment.

In routine clinical practice, LN resection in GC patients is generally not up to D2 lymphadenectomy standard, despite D2 lymphadenectomy being regarded as the standard surgical technique in Eastern Asian countries ([@b21-ol-06-06-1693],[@b22-ol-06-06-1693]). Certain studies did not consider this factor in the inclusion criteria ([@b17-ol-06-06-1693],[@b23-ol-06-06-1693],[@b27-ol-06-06-1693],[@b30-ol-06-06-1693]), weakening the credibility of the results. In this study, only patients with \>15 LN resections were included. However, pN is correlated with surgery, whereas LNR is not. Therefore, in univariate and multivariate analyses, both pN and LNR were independent prognostic factors, indicating that LNR was closely associated with prognosis, similar to pN. Moreover, the LNR and TRM staging system could better discriminate subgroups ([Figs. 3](#f3-ol-06-06-1693){ref-type="fig"} and [4](#f4-ol-06-06-1693){ref-type="fig"}), as confirmed by other studies ([@b17-ol-06-06-1693],[@b23-ol-06-06-1693]--[@b27-ol-06-06-1693],[@b29-ol-06-06-1693]). From this perspective, LNR was a better prognosticator than pN.

As to the predictive accuracy analysis, there has been no validated standard. The most commonly used methods were the area under the curve by ROC analysis, the concordance index, explained variation and a summary measure of separation ([@b31-ol-06-06-1693]). In this study, the TRM staging system had the maximal area under the curve by ROC, and LNR also had a bigger area than pN.

In conclusion, LNR may be a better prognosticator than pN for the following reasons: i) LNR has no correlation with surgery; ii) there were 55 (39.9%) GC patients down-staged and no patients upstaged in the TRM staging system; iii) in univariate and multivariate analysis, both LNR and pN were independent prognostic factors; iv) the LNR and TRM staging system were capable of better differentiating patients than the pN and TNM staging system; v) in ROC analysis, the LNR and TRM staging system have a greater area than the pN and TNM staging system, respectively. The resulting TRM staging system may better predict the clinical outcomes.
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###### 

The characteristics and univariate analysis of 138 patients with GC.

  Variables               n (%)        Events (%)   Median OS (95% CI) (months)   P-value
  ----------------------- ------------ ------------ ----------------------------- ---------
  Hospital                                                                        0.374
   Zhongnan Hospital      53 (38.4)    34 (64.2)    25.0 (15.4--34.6)             
   Heji Hospital          43 (31.2)    21 (48.4)    38.9 (35.0--42.8)             
   Hubei Tumor Hospital   42 (30.4)    21 (50.0)    34.1 (27.8--40.4)             
  Gender                                                                          0.171
   Male                   99 (71.7)    52 (52.5)    36.4 (25.8--47.0)             
   Female                 39 (28.3)    24 (61.5)    27.0 (16.3--37.7)             
  Age (years)                                                                     0.216
   ≤65                    101 (73.2)   52 (51.5)    36.4 (17.5--55.3)             
   \>65                   37 (26.8)    24 (64.9)    25.0 (16.1--33.9)             
  Cancer site                                                                     0.020
   Upper third            31 (22.5)    14 (45.2)    31.1 (25.6--36.5)             
   Middle third           27 (19.6)    15 (55.6)    25.0 (10.9--39.1)             
   Lower third            70 (50.7)    39 (55.7)    36.4 (25.3--47.5)             
   Whole stomach          10 (7.2)     8 (80.0)     8.7 (4.1--13.4)               
  Pathological type                                                               0.126
   Intestinal             106 (76.8)   57 (53.8)    35.9 (25.7--46.1)             
   Diffuse                12 (8.7)     5 (41.7)     25.9 (19.3--32.4)             
   Mixed                  20 (14.5)    14 (70.0)    14.1 (8.2--20.0)              
  Surgery type                                                                    0.044
   Proximal gastrectomy   36 (26.1)    16 (44.4)    30.7 (25.4--36.0)             
   Distant gastrectomy    81 (58.7)    44 (54.3)    36.4 (25.6--47.2)             
   Total gastrectomy      21 (15.2)    16 (76.2)    13.4 (1.9--24.9)              
  Tumor invasion                                                                  0.004
   T1                     6 (4.3)      2 (33.3)     43.5 (26.3--60.7)             
   T2                     21 (15.2)    4 (19.0)     75.0 (61.3--88.8)             
   T3                     1 (0.7)      1 (100.0)    15.8 (15.8--15.8)             
   T4a                    79 (57.2)    48 (60.8)    28.2 (16.7--39.7)             
   T4b                    31 (22.5)    21 (67.7)    17.5 (10.4--24.6)             
  pN                                                                              \<0.001
   N0                     33 (23.9)    10 (30.3)    64.4 (50.9--77.9)             
   N1                     19 (13.8)    7 (36.8)     61.5 (44.4--78.6)             
   N2                     25 (18.1)    14 (56.0)    27.0 (15.4--38.6)             
   N3                     61 (44.2)    45 (73.8)    14.6 (8.4--20.8)              
  LNR                                                                             \<0.001
   R0                     33 (23.9)    10 (30.3)    64.4 (50.9--77.9)             
   R1                     68 (49.3)    34 (50.0)    37.8 (19.6--56.0)             
   R2                     24 (17.4)    19 (79.2)    13.8 (6.4--21.2)              
   R3                     13 (9.4)     13 (100.0)   7.5 (2.2--12.7)               
  Distant metastases                                                              \<0.001
   M0                     128 (92.8)   66 (51.6)    36.4 (27.8--45.0)             
   M1                     10 (7.2)     10 (100.0)   11.4 (7.6--15.1)              
  TNM staging                                                                     \<0.001
   I                      18 (13.0)    3 (16.7)     77.2 (63.4--91.0)             
   II                     19 (13.8)    7 (36.8)     43.4 (32.3--54.5)             
   IIIA                   17 (12.3)    6 (35.3)     64.5 (47.7--81.3)             
   IIIB                   15 (10.9)    9 (60.0)     28.0 (25.0--31.0)             
   IIIC                   61 (44.2)    43 (70.5)    14.6 (8.6--20.5)              
   IV                     8 (5.8)      8 (100.0)    11.4 (2.1--20.7)              
  TRM staging                                                                     \<0.001
   I                      18 (13.0)    3 (16.7)     77.2 (63.4--91.0)             
   II                     20 (14.5)    7 (35.0)     44.3 (33.4--55.1)             
   IIIA                   40 (29.0)    21 (52.5)    36.4 (4.3--68.5)              
   IIIB                   32 (23.2)    17 (53.1)    25.0 (10.1--39.9)             
   IIIC                   20 (14.5)    20 (100.0)   11.3 (9.1--13.5)              
   IV                     8 (5.8)      8 (100.0)    11.4 (2.1--20.7)              
  Postoperative SAE                                                               \<0.001
   No                     118 (85.5)   57 (48.3)    38.9 (20.7--57.1)             
   Yes                    20 (14.5)    19 (95.0)    13.4 (5.9--20.9)              
  Chemotherapy                                                                    0.183
   No                     52 (37.7)    31 (59.6)    23.5 (14.5--32.5)             
   Yes                    86 (62.3)    45 (52.3)    37.8 (22.2--53.4)             

GC, gastric cancer; CI, confidence interval; pN, lymph node status; LNR, lymph node ratio; TNM staging, tumor-node-metastases staging; TRM staging, tumor-node-ratio-metastases staging; SAE, serious adverse event; OS, overall survival.

###### 

Independent prognostic factors of 138 GC patients identified by multivariate analysis.

  Variables            χ^2^     Hazard ratio (95% CI)    P-value
  -------------------- -------- ------------------------ ---------
  TNM-based                                              
  pN                                                     0.004
   N0 (reference)                                        
   N1                  0.356    1.342 (0.510--3.531)     0.551
   N2                  4.022    2.301 (1.019--5.193)     0.045
   N3                  11.120   3.319 (1.640--6.718)     0.001
  Postoperative SAE                                      0.014
   No (reference)                                        
   Yes                 6.034    1.991 (1.149--3.449)     
  TRM-based                                              
  LNR                                                    \<0.001
   R0 (reference)                                        
   R1                  2.515    1.775 (0.873--3.609)     0.113
   R2                  18.771   5.636 (2.578--12.321)    \<0.001
   R3                  34.116   15.113 (6.076--37.591)   \<0.001
  Distant metastases                                     0.006
   No (reference)                                        
   Yes                 7.685    2.728 (1.342--5.548)     

GC, gastric cancer; CI, confidence interval; pN, lymph node status; SAE, serious adverse event; LNR, lymph node ratio.

###### 

Predictive value of the factors assessed in ROC analysis.

                               95% CI                   
  -------------------- ------- -------- ------- ------- ---------
  TRM staging system   0.769   0.692    0.845   0.039   \<0.001
  TNM staging system   0.745   0.662    0.827   0.042   \<0.001
  LNR classification   0.724   0.641    0.807   0.042   \<0.001
  pN classification    0.704   0.615    0.792   0.045   \<0.001

ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval; Std. error, standard error; TRM staging, tumor-node ratio-metastases staging; TNM staging, tumor-node-metastases staging; LNR, lymph node ratio; pN, lymph node status.

###### 

Information on LNR from previous studies and the present study.

  Authors (ref.)                          No. of patients   No. of removed LNs (range)                                  Cutoff points of LNR   5-year survival rates of R0, R1, R2, R3 (%)
  --------------------------------------- ----------------- ----------------------------------------------------------- ---------------------- ---------------------------------------------
  Kim *et al*([@b19-ol-06-06-1693])       529               6[a](#tfn4-ol-06-06-1693){ref-type="table-fn"}(1--104)      0, 0.30, 0.60          71.7, 35.7, 16.3, 0
  Asoglu *et al*([@b20-ol-06-06-1693])    264               27[b](#tfn5-ol-06-06-1693){ref-type="table-fn"}(16--75)     0, 0.10, 0.25          86.9, 81.1, 47.1, 24.7
  Xu *et al*([@b21-ol-06-06-1693])        177               20[a](#tfn4-ol-06-06-1693){ref-type="table-fn"}(16--53)     0, 0.10, 0.25          84.3, 71.1, 45.1, 24.2
  Lee *et al*([@b22-ol-06-06-1693])       342               28.9[b](#tfn5-ol-06-06-1693){ref-type="table-fn"}(16--98)   0, 0.30, 0.60          Unknown
  Huang *et al*([@b23-ol-06-06-1693])     634               23[a](#tfn4-ol-06-06-1693){ref-type="table-fn"}(5--61)      0, 0.20, 0.50          83.3, 68.4, 40.7, 17.2
  Feng *et al*([@b24-ol-06-06-1693])      109               38.34[b](#tfn5-ol-06-06-1693){ref-type="table-fn"}          0, 0.10, 0.25          58.8, 43.8, 25.0, 10.4
  Lemmens *et al*([@b25-ol-06-06-1693])   880               7[a](#tfn4-ol-06-06-1693){ref-type="table-fn"} (unknown)    0, 0.20, 0.30          58, 50, 18, 11
  Wang *et al*([@b16-ol-06-06-1693])      1343              15[b](#tfn5-ol-06-06-1693){ref-type="table-fn"}(3--72)      0, 0.30, 0.60          77.5, 64.3, 39.7, 22.3
  Qiu *et al*([@b26-ol-06-06-1693])       730               16[a](#tfn4-ol-06-06-1693){ref-type="table-fn"} (0--72)     0, 0.30, 0.60          72.1, 65.6, 30.3, 13.0
  Present study                           138               21[a](#tfn4-ol-06-06-1693){ref-type="table-fn"}(16--47)     0, 0.50, 0.80          69.7, 52.9, 20.8, 0

Median number of removed LNs;

mean number of removed LNs.

LNR, lymph node ratio; LN, lymph node.
